Kiniksa Pharmaceuticals International, plc (KNSA) Guidance & Earnings Results
On 2026-07-28 Kiniksa Pharmaceuticals International, plc raised guidance: "2026 ARCALYST guidance raised to $980-995M from…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KNSAKiniksa Pharmaceuticals International, plcFollow KNSA — free
—
Price chart with a free account
- Market cap
- 6.0B
- P/E TTM
- 78.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 26 Oct, in 2 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 28 Jul 26 | Raised | 2026 ARCALYST guidance raised to $980-995M from $930-945M · full year |
| 28 Apr 26 | Raised | 2026 ARCALYST net product revenue raised to $930-945M from $900-920M · full year |
| 24 Feb 26 | Raised | 2026 ARCALYST revenue guidance $900M-$920M · full year |
| 12 Jan 26 | Raised | 2026 ARCALYST net product revenue guidance $900-920M vs 2025 actual $677.5M |
| 28 Oct 25 | Raised | 2025 ARCALYST net product revenue guidance raised to $670-675M from $625-640M · full year |
| 29 Jul 25 | Raised | FY2025 ARCALYST net product revenue raised to $625-640M from $590-605M · full year |
Kiniksa Pharmaceuticals International, plc — questions
- What guidance did Kiniksa Pharmaceuticals International, plc give?
- On 2026-07-28: "2026 ARCALYST guidance raised to $980-995M from $930-945M"
- When does Kiniksa Pharmaceuticals International, plc report earnings?
- Kiniksa Pharmaceuticals International, plc's next earnings report is expected on 2026-10-26.
Every figure on this page comes from Kiniksa Pharmaceuticals International, plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.